CARTHERICS

The Future of Cancer Treatment

Our strategy

October 2019



Cartherics Pty Ltd


- Founded 2015
- Laboratories and offices at Monash Health Translation Precinct, Melbourne, Australia
- Series A financing AU\$5M completed late 2015
- Series B Financing AU\$5M (plus an optional AU\$1.3M)
- Federal and State Grants AU\$3.5M
- Company operations commenced January 2016.

Preparing for two Phase I/II Autologous Clinical Trials

- 1. Cutaneous T Cell Lymphoma
 - Product CTH-001 (anti-TAG-72 CAR-T cells)

- 2. Relapsed Ovarian Cancer
 - Product CTH-004 (anti-TAG-72; + gene k/o CAR-T cells)








Initial cancer target: TAG-72


- Glycoprotein found on the surface of many types of cancer cells, including breast, colon, gastric, lung, pancreatic and ovarian cancers (+ T Cell Lymphoma)
- Human tissue distribution studies have shown >95% of serous and >85% of clear cell ovarian cancers are TAG-72 positive
 - Expression levels increase in malignant disease.





The future of cancer treatment. Combining stem cells and immunotherapy.


Killing human ovarian cancer xenografts in NSG mice : CTH-001 (anti TAG-72)



- Ovcar 3 Tumors grown to 100m³;
- TAG72 CAR-T cells injected 3 times, 5 days apart;
- Control mice given non-transduced T cells;
- All controls had to be culled by 40 days;
- TAG 72 CAR-T cells showed strong reduction in tumor size to 70 days

CAR herics


Killing human ovarian cancer xenografts in NSG mice : CTH-004 (anti TAG-72 + gene K/O)





Histology of human tumours and remnants

OVCAR3 - CTH-004 100 days



CAR herics


The future of cancer treatment. Combining stem cells and immunotherapy.

T cell lymphomas express elevated TAG-72

- There is a strong precedent for treatment of lymphomas with CAR-T cells
- A significant proportion (>40%) of patients with T cell lymphoma (TCL) show elevated levels of circulating TAG-72+ T cells
 o Cartherics' CTH-001 cells kill these T cells - see next slide
- There are very few therapeutic options available for these patients
- Cartherics to study Cartherics CTH-001 as an autologous therapy for TCL.




Tag-72+ Cutaneous T Cell Lymphoma (CTCL) patients: CTH-001



CAR herics

Off-the-shelf – Allogeneic cancer therapy



The future of cancer treatment. Combining stem cells and immunotherapy.


CAR herics

Cartherics is also preparing for

- 'first in human' Phase I/II Allogeneic CAR-NK cell clinical trial, Product CTH-401; relapsed ovarian cancer, and
- product developed through Federal Government CRC-P Grant of AU\$3 Million to Cartherics, Mesoblast, Cell Therapies, Monash University and Hudson Institute of Medical Research.



iPSC to NK method of manufacture



Overview


12

- Total time: 30 days
- Method designed on patterning cell development that mimics natural NK development in the body
- Focus on xeno-free, scalable, molecularly-defined and clinically translatable systems
- ~150,000 iNK cells per iPSC





iNK Cytotoxic function on ovarian cancer cells in vitro



Take home message:

- 1. iPSC derived NK cells kill ovarian cancer in vitro
- 2. iPSC-NK cells function similar to normal NKS
- 3. TAG-72 CAR iNK increases killing of ovarian cancer



Company relationships

14

- Mesoblast CRC partner
- Cell Therapies (Peter Mac) CRC partner, Manufacturing partner
- ToolGen Partnership for gene editing
- PanCella Partnership for Immuno-cloaking and Fail-safe technology
- Berry Genomics Genomics partnership.

